Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.73 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.73 |
| ▸ | FNTA | P49354 | 2/20 | 0.48 |
| ▸ | FNTB | P49356 | 2/20 | 0.48 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.42 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9270945 | 1.00 | ALDH1A1 (0.73) | ALDH1A1ALOX15FNTAFNTBPGGT1B | |
| SCHEMBL3083781 | 1.00 | ALDH1A1 (0.73) | ALDH1A1ALOX15FNTAFNTBPGGT1B | |
| SCHEMBL9270948 | 1.00 | ALDH1A1 (0.73) | ALDH1A1ALOX15FNTAFNTBPGGT1B | |
| SCHEMBL1073135 | 1.00 | ALDH1A1 (0.73) | ALDH1A1ALOX15FNTAFNTBPGGT1B | |
| SCHEMBL5372580 | 0.88 | ALDH1A1 (0.59) | ALDH1A1ALOX15PTPN1BTN3A1 | |
| SCHEMBL9013663 | 0.88 | ALDH1A1 (0.59) | ALDH1A1ALOX15PTPN1BTN3A1 | |
| SCHEMBL11410939 | 0.87 | ALDH1A1 (0.96) | ALDH1A1ALOX15FNTAFNTBPGGT1B | |
| SCHEMBL806725 | 0.87 | ALDH1A1 (0.96) | ALDH1A1ALOX15FNTAFNTBPGGT1B | |
| SCHEMBL1301763 | 0.87 | ALDH1A1 (0.96) | ALDH1A1ALOX15FNTAFNTBPGGT1B | |
| SCHEMBL1301765 | 0.87 | ALDH1A1 (0.96) | ALDH1A1ALOX15FNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12264349-B2 | Method for producing monoterpenoid compounds | JOHN INNES CENTRE (GB) | 2025-04-01 | — | — | US | disclosed |
| WO-2023204271-A1 | ANTI-SARS-COV-2 AGENT AND COMPOUND USE | 国立大学法人 鹿児島大学 | 2023-10-26 | — | — | WO | disclosed |
| US-20230250041-A1 | METHOD AND INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF MENAQUINONE MK-7 | VitaSynth Sp. z.o.o. (PL) | 2023-08-10 | — | — | US | disclosed |
| US-20230250041-A1 | METHOD AND INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF MENAQUINONE MK-7 | VitaSynth Sp. z.o.o. (PL) | 2023-08-10 | — | — | US | disclosed |
| US-11407704-B2 | Process of vitamin K2 derivatives preparation | SIEC BADAWCZA LUKASIEWICZ-INSTYTUT CHEMII PRZEMYSLOWEJ IMIENIA PROFESORA IGNACEGO MOSCICKIEGO (PL) | 2022-08-09 | — | — | US | disclosed |
| US-11407704-B2 | Process of vitamin K2 derivatives preparation | SIEC BADAWCZA LUKASIEWICZ-INSTYTUT CHEMII PRZEMYSLOWEJ IMIENIA PROFESORA IGNACEGO MOSCICKIEGO (PL) | 2022-08-09 | — | — | US | disclosed |
| US-20210317060-A1 | PROCESS OF VITAMIN K2 DERIVATIVES PREPARATION | SIEC BADAWCZA LUKASIEWICZ-INSTYTUT CHEMII PRZEMYSLOWEJ IMIENIA PROFESORA IGNACEGO MOSCICKIEGO (PL) | 2021-10-14 | — | — | US | disclosed |
| US-20210317060-A1 | PROCESS OF VITAMIN K2 DERIVATIVES PREPARATION | SIEC BADAWCZA LUKASIEWICZ-INSTYTUT CHEMII PRZEMYSLOWEJ IMIENIA PROFESORA IGNACEGO MOSCICKIEGO (PL) | 2021-10-14 | — | — | US | disclosed |
| US-20210207183-A1 | METHOD FOR PRODUCING MONOTERPENOID COMPOUNDS | JOHN INNES CENTRE (GB) | 2021-07-08 | — | — | US | disclosed |
| WO-2021071372-A1 | PROCESS OF VITAMIN K2 DERIVATIVES PREPARATION | SIEĆ BADAWCZA ŁUKASIEWICZ - INSTYTUT FARMACEUTYCZNY (PL) | 2021-04-15 | — | — | WO | disclosed |
| US-6867333-B2 | EPOTHILONE SYNTHESIS BUILDING BLOCKS III AND IV: ASYMMETRICALLY SUBSTITUTED ACYLOINS AND ACYLOIN DERIVATIVES, METHODS FOR THEIR PRODUCTION AND METHODS FOR THE PRODUCTION OF EPOTHILONES B, D AND EPOTHILONE DERIVATIVES | MORPHOCHEM AG (DE) | 2005-03-15 | — | — | US | disclosed |
| US-20040082651-A1 | Epothilone synthesis building blocks III and IV: asymmetrically substituted acyloins and acyloin derivatives, methods for their production and methods for the production of epothilones B, D and epothilone derivatives | R & D BIOPHARMACEUTICALS GMBH (DE) | 2004-04-29 | — | — | US | disclosed |
| US-6726911-B1 | SOLVENT EXTRACT; MICROBIOCIDES; ENDOPEPTIDASE, ANGIOTENSIN CONVERTING ENZYME AND SERUM-MEDIATED-BINDING OF LIPOPOLYSACCHARIDE INHIBITORS | GANOMYCIN (DE) | 2004-04-27 | — | — | US | disclosed |
| US-5354874-A | Intermediates for Sarcophytol A; antitumor, anticarcinogenic agent | MITSUBISHI KASEI CORPORATION (JP) | 1994-10-11 | — | — | US | disclosed |
| US-5324869-A | Chemical intermediates for sarcophytol a | MITSUBISHI KASEI CORPORATION (JP) | 1994-06-28 | — | — | US | disclosed |
| US-5304661-A | Chemical intermediate for sarcophytol a | MITSUBISHI KASEI CORPORATION (JP) | 1994-04-19 | — | — | US | disclosed |
| US-5245085-A | Chemical intermediates for sarcophytol A, an anticancer and antitumor agent | MITSUBISHI KASEI CORPORATION (JP) | 1993-09-14 | — | — | US | disclosed |
| EP-0455826-A1 | SUBSTITUTED OPEN-CHAIN TERPENE COMPOUND | Mitsubishi Chemical Corporation (JP) | 1991-11-13 | — | — | EP | disclosed |
| US-4199519-A | TREATMENT OF PEPTIC ULCERS | SANKYO COMPANY LIMITED (JP) | 1980-04-22 | — | — | US | disclosed |
| US-4151357-A | FOR PEPTIC ULCERS | SANKYO COMPANY LIMITED (JP) | 1979-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11407704-B2 | Process of vitamin K2 derivatives preparation | PROC, VKORC1, VKORC1L1 | ALDH1A1 1623/4885ALOX15 2307/4885FNTA 656/4885 |
| US-20230250041-A1 | METHOD AND INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF MENAQUINONE MK-7 | SIRT7, NDUFS7, SDHA | ALDH1A1 778/4885ALOX15 2142/4885FNTA 701/4885 |
| US-20040082651-A1 | Epothilone synthesis building blocks III and IV: asymmetrically substituted acyloins and acyloin derivatives, methods for their production and methods for the production of epothilones B, D and epothilone derivatives | COASY, ACOX1, FDFT1 | ALDH1A1 1538/4885ALOX15 89/4885FNTA 29/4885 |
| US-20210317060-A1 | PROCESS OF VITAMIN K2 DERIVATIVES PREPARATION | PROC, VKORC1, VKORC1L1 | ALDH1A1 1623/4885ALOX15 2307/4885FNTA 656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.